Maximus/$MMS
1D1W1MYTD1Y5YMAX
Capital at risk
About Maximus
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
- Ticker
- $MMS
- Sector
- Business services
- Primary listing
- NYSE
- Employees
- 37,200
- Headquarters
- McLean, United States
- Website
- www.maximus.com
Maximus Metrics
BasicAdvanced
$3B
8.55
$6.74
0.59
$1.29
2.29%
Price and volume
Market cap
$3B
Beta
0.59
52-week high
$100.00
52-week low
$52.73
Average daily volume
595K
Dividend rate
$1.29
Financial strength
Current ratio
2.421
Quick ratio
2.168
Long term debt to equity
0.932
Total debt to equity
0.995
Dividend payout ratio (TTM)
18.41%
Interest coverage (TTM)
6.49%
Profitability
EBITDA (TTM)
691.836
Gross margin (TTM)
25.59%
Net profit margin (TTM)
7.07%
Operating margin (TTM)
11.03%
Effective tax rate (TTM)
24.53%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
8.20%
Return on equity (TTM)
21.11%
Valuation
Price to earnings (TTM)
8.551
Price to revenue (TTM)
0.599
Price to book
1.73
Price to tangible book (TTM)
-4.2
Price to free cash flow (TTM)
7.255
Free cash flow yield (TTM)
13.78%
Free cash flow per share (TTM)
7.94
Dividend yield (TTM)
2.24%
Forward dividend yield
2.29%
Growth
Revenue change (TTM)
-3.32%
Earnings per share change (TTM)
25.45%
3-year revenue growth (CAGR)
2.87%
10-year revenue growth (CAGR)
8.33%
3-year earnings per share growth (CAGR)
34.10%
10-year earnings per share growth (CAGR)
10.66%
3-year dividend per share growth (CAGR)
4.00%
10-year dividend per share growth (CAGR)
21.48%
What the Analysts think about Maximus
Analyst ratings (Buy, Hold, Sell) for Maximus stock.
Analyst projections of the future price of Maximus stock.
Bulls say / Bears say
Maximus reported Q2 adjusted EPS of $2.07, exceeding the analyst consensus of $2.02, and raised its full-year FY26 adjusted EPS guidance by $0.20 to a range of $8.25–$8.55, attributing the boost to automation and AI-driven efficiency gains (Reuters)
The Board of Directors authorized a refresh of its share repurchase program for up to $400 million effective May 11, 2026, demonstrating management’s confidence in the company’s cash flow generation and commitment to returning capital to shareholders (Maximus 8-K)
As of June 30, 2026, year-to-date signed contract awards totaled $1.25 billion, with an additional $1.35 billion pending, underscoring a robust backlog and strong future revenue visibility (Maximus 10-Q)
Q2 revenue of $1.31 billion missed consensus by $11.94 million and declined 4.1% year-over-year, underlining top-line pressures in its core federal services business (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Maximus Financial Performance
Revenues and expenses
Maximus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Maximus News
AllArticlesVideos
Funds containing Maximus
AllUSDEURGBP
Fund name | Fund size | $MMS weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.32% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.32% |
iShares Healthcare Innovation£DRDR | £1B | 0.32% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.